Ixazomib Plus Standard Therapy for Myeloma: Outcomes in Routine Clinical Practice
Posted: Wednesday, February 10, 2021
For patients with relapsed and refractory multiple myeloma, therapeutic intervention with the triple pharmacologic regimen of ixazomib, lenalidomide, and dexamethasone (IRD) led to better patient outcomes, according to the TOURMALINE-MM1 study published in BMC Cancer. The addition of ixazomib to the original treatment regimen may have led to this positive outcome for patients, explained Jiri Minarik, MD, PhD, of the Palacky University Olomouc, Czech Republic, and colleagues, in their head-to-head comparison of IRD and lenalidomide/dexamethasone in routine clinical practice.
From 2016 to 2018, a total of 344 patients with relapsed and refractory multiple myeloma were recruited from the Czech Registry of Monoclonal Gammopathies. Patients were stratified into two treatment groups and received either IRD (n = 127) or lenalidomide/dexamethasone (n = 217). Patients were given 4 mg of ixazomib on days 1, 8, and 15; 25 mg of lenalidomide on days 1 through 21; and 20 to 40 mg of dexamethasone on days 1, 8, 15, and 22. As a precaution, all patients received thromboprophylaxis.
The study findings revealed a median progression-free survival of 17.5 months and 11.5 months for patients receiving IRD and lenalidomide/dexamethasone, respectively. The hazard ratio for this progression-free survival was 0.67 (P = .006). In addition, patients receiving IRD demonstrated an increased overall survival of 36.6 months compared with patients receiving lenalidomide/dexamethasone (overall survival = 26 months). Furthermore, the overall response rates were 73% and 66.2% with IRD and lenalidomide/dexamethasone, respectively. Moreover, the complete response rate was 11.1% with IRD and 8.8% with lenalidomide/dexamethasone. Both pharmacologic treatments were reported to be well tolerated, with similar grade 3 and 4 adverse effects.
Disclosure: For full disclosures of the study authors, visit bmccancer.biomedcentral.com.